UK markets close in 41 minutes

BioPorto A/S (THOXF)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
0.75000.0000 (0.00%)
As of 9:36AM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close0.7500
Open0.7500
BidN/A x N/A
AskN/A x N/A
Day's range0.7500 - 0.7500
52-week range0.3578 - 0.8000
Volume4,000
Avg. volume139
Market cap175.934M
Beta (5Y monthly)1.15
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Globe Newswire

    Peter Mørch Eriksen resigns as CEO of BioPorto A/S

    May 5, 2021Announcement no. 10 Peter Mørch Eriksen resigns as CEO of BioPorto A/S After having led BioPorto as CEO for almost 8 years, BioPorto’s Chief Executive Officer, is resigning his position as CEO of the Company. Peter will continue to support the Company until end of January 2022, and will retain his position as CEO until his successor has been found. Peter Mørch Eriksen says: “It is, and has been, a privilege to be CEO of BioPorto, and I look forward to continue to support the Company’s ongoing projects, including the clinical studies and expected submission this summer of a De Novo application to the FDA for pediatric use of The NGAL Test™. Considering the important milestones ahead for BioPorto, I find this to be the right time to find my successor who can lead the Company into its next phase.” Thomas Magnussen, Chairman of the Board of Directors, says: “I wish to thank Peter for his tremendous efforts for the Company over many years. I and the rest of the organization look forward to continue working with Peter over the coming months, as we proceed to identify and appoint his successor and further advance the ongoing transition of the Company to the North American market.” For further information, please contact: Thomas Magnussen, Chairman of the Board Telephone +45 3177 0000, e-mail: investor@bioporto.com About BioPorto BioPorto is an in vitro diagnostics company that provides tests and antibodies to clinicians and researchers around the world. We use our antibody and assay expertise to transform novel research tools into clinically actionable biomarkers that can make a difference in patients’ lives. BioPorto is headquartered in Hellerup, Denmark and is listed on the NASDAQ Copenhagen stock exchange [CPH:BIOPOR]. Attachment 2021 05 05 - Company announcement no. 10

  • Globe Newswire

    BioPorto A/S - Annual General Meeting

    April 29, 2021Announcement no. 9 BioPorto A/S - Annual General Meeting Today, BioPorto A/S held its Annual General Meeting during which the report on the Company’s activities was reviewed and the 2020 Annual Report was adopted. The proposed allocation of the results was also adopted and discharge of liability was granted to the Board of Directors and the Executive Management. The remuneration report 2020 was approved by advisory vote, and the remuneration for the Board of Directors was approved. Thomas Magnussen, Christopher Lindop and Michael S. Singer were re-elected as members of the Board of Directors. Don M. Hardison, John McDonough and Jan Leth Christensen were elected as new members of the Board of Directors. The proposals from the Board of Directors under item 7 of the agenda were all adopted and included: a) Renewal of the authorisation to increase the share capital, subject to a limit of DKK 100,000,000 for pre-emptive issues and a limit of DKK 30,000,000 for issues without pre-emptive rights with the option of an additional DKK 70,000,000 for offerings where the new shares are admitted to trading on a stock exchange, etc. other than Nasdaq Copenhagen, b) Renewal of the authorisation to issue warrants and amend warrant terms, however limited so that (i) the aggregate number of warrants outstanding shall not exceed the equivalent of 10% of the Company’s share capital from time to time; and that (ii) the maximum share capital increase pursuant the authorisation shall be DKK 10,000,000, c) Adoption of an amendment to the Remuneration Policy to authorise the Board of Directors to implement an indemnification scheme for members of the Board of Directors and the Executive Management, d) Authorisation to the Chairman of the general meeting. PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab was re-elected as the Company’s auditor. Immediately following the Annual General Meeting, the Board of Directors elected Thomas Magnussen as Chairman and Christopher Lindop as Vice Chairman. Hellerup, April 29, 2021 BioPorto A/S The Board of Directors For further information, please contact: Peter Mørch Eriksen, CEO Telephone +45 4529 0000, e-mail: investor@bioporto.com About BioPorto BioPorto is an in vitro diagnostics company that provides tests and antibodies to clinicians and researchers around the world. We use our antibody and assay expertise to transform novel research tools into clinically actionable biomarkers that can make a difference in patients’ lives. BioPorto is headquartered in Hellerup, Denmark and is listed on the NASDAQ Copenhagen stock exchange [CPH:BIOPOR]. Attachment 2021 04 29 Announcement no. 9

  • Globe Newswire

    BioPorto initiates search for new CFO as Ole Larsen resigns

    April 26, 2021Announcement no. 8 BioPorto initiates search for new CFO as Ole Larsen resigns Having served as Chief Financial Officer (CFO) and member of the management team of BioPorto A/S since 2018, Ole Larsen has today tendered his resignation to pursue other opportunities outside BioPorto. “It is with regret that we received Ole’s resignation. He has been a truly important asset for BioPorto. During his three-year tenure, he has established a strong performing finance organization while focusing on broadening our investor reach and dialogue which has been pivotal in execution of our funding strategy. I am grateful for his strong contribution and wish him all the best in his future endeavors,” says Peter Mørch Eriksen, CEO of BioPorto. Ole will leave the Company by the end of May 2021 and remain available for the Company until the end of October 2021. The search for a successor will be initiated immediately and we will communicate as soon as we have concluded on the search process. The content of this announcement does not alter BioPorto’s financial guidance for 2021 as most recently presented in the Annual Report for 2020. Hellerup, April 26, 2021 BioPorto A/S For further information, please contact: Peter Mørch Eriksen, CEO BioPorto A/S Telephone + 45 4529 0000, email investor@bioporto.com About BioPorto BioPorto is an in vitro diagnostics company that provides tests and antibodies to clinicians and researchers around the world. We use our antibody and assay expertise to transform novel research tools into clinically actionable biomarkers that can make a difference in patients’ lives. BioPorto is headquartered in Hellerup, Denmark and is listed on the NASDAQ Copenhagen stock exchange [CPH:BIOPOR]. Attachment 2021 04 26 Announcement no. 8